Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 6/20 | 0.47 |
| ▸ | ELANE | P08246 | 4/20 | 0.43 |
| ▸ | XIAP | P98170 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | MLX | Q9UH92 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31031582 | 0.91 | XIAP (0.48) | CALCRLELANEXIAPSLC6A2MLX | |
| SCHEMBL29590865 | 0.85 | XIAP (0.50) | CALCRLXIAPKEAP1 | |
| SCHEMBL23135343 | 0.82 | XIAP (0.53) | CALCRLELANEXIAPSLC6A2 | |
| SCHEMBL23135342 | 0.82 | XIAP (0.53) | CALCRLELANEXIAPSLC6A2 | |
| SCHEMBL8627244 | 0.82 | CALCRL (0.47) | CALCRLXIAPSLC6A2KEAP1RAMP1 | |
| SCHEMBL29733288 | 0.81 | CALCRL (0.51) | CALCRLXIAPSLC6A2RAMP1 | |
| SCHEMBL29477197 | 0.81 | XIAP (0.47) | CALCRLELANEXIAPSLC6A2MLX | |
| SCHEMBL31031596 | 0.80 | C5AR1 (0.44) | — | |
| SCHEMBL29630819 | 0.80 | XIAP (0.47) | CALCRLXIAPSLC6A2 | |
| SCHEMBL30123263 | 0.79 | SLC6A2 (0.52) | CALCRLXIAPSLC6A2RAMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409524-A1 | COMPOUND HAVING PHOTOCLEAVABLE MOIETY, CONJUGATE, AND SCREENING METHOD USING SAME | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2024-12-12 | — | — | US | disclosed |
| EP-4378944-A1 | COMPOUND HAVING PHOTOCLEAVABLE SITE, LINKER, AND SCREENING METHOD USING SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-06-05 | — | — | EP | disclosed |
| CN-117980308-A | Compound having photocleavable site, joined body, and screening method using same | 中外制药株式会社 | 2024-05-03 | — | — | CN | disclosed |
| WO-2023054636-A1 | COMPOUND HAVING PHOTOCLEAVABLE SITE, LINKER, AND SCREENING METHOD USING SAME | 中外製薬株式会社 | 2023-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409524-A1 | COMPOUND HAVING PHOTOCLEAVABLE MOIETY, CONJUGATE, AND SCREENING METHOD USING SAME | ALDH1A2, FOLH1, TACR1 | CALCRL 2137/4885ELANE 1912/4885XIAP 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.